

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (previously presented) An isolated biopolymer marker peptide consisting of amino acid residues 2-11 of SEQ ID NO:1 diagnostic for myocardial infarction, congestive heart failure or intracerebral hemorrhage.

Claims 2-35. (cancelled)

Claim 36. (currently amended) A method for diagnosing myocardial infarction, congestive heart failure ~~[[and]]~~ or intracerebral hemorrhage comprising:

(a) obtaining a sample from a patient;

~~(b) conducting mass spectrometric analysis on said sample in a manner effective to maximize elucidation of discernible peptide fragments contained therein, and~~

(b) preparing said sample to maximize the diversity of biopolymers discernible from said sample;

(c) conducting mass spectrometric analysis on said sample; and

~~[[c)]]~~ (d) comparing mass spectrum profiles of a peptide consisting of amino acid residues 2-11 of SEQ ID NO:1 to mass

spectrum profiles of ~~peptides elucidated~~ biopolymers discerned from said sample; wherein recognition of a mass spectrum profile in the sample displaying the characteristic profile of the mass spectrum profile for the peptide consisting of amino acid residues 2-11 of SEQ ID NO:1 is diagnostic for myocardial infarction, congestive heart failure ~~[[and]]~~ or intracerebral hemorrhage.

Claim 37. (previously presented) The method of claim 36, wherein the sample is an unfractionated body fluid or a tissue sample.

Claim 38. (previously presented) The method of claim 36, wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 39. (previously presented) The method of claim 36, wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).

Claim 40. (previously presented) The method of claim 36, wherein said patient is a human.

Claim 41. (currently amended) ~~A myocardial infarction, congestive heart failure and intracerebral hemorrhage diagnostic kit~~ A kit for determining the presence of an isolated biopolymer marker peptide consisting of amino acid residues 2-11 of SEQ ID NO:1 comprising: (a)[[a]] an isolated biopolymer marker peptide consisting of amino acid residues 2-11 of SEQ ID NO:1 and (b) an antibody that binds to said peptide in a sample from a patient.

Claim 42. (currently amended) The ~~diagnostic assay~~ kit of claim 41, wherein said antibody is immobilized on a solid support.

Claim 43. (currently amended) The ~~diagnostic~~ kit of claim 41, wherein said antibody is labeled.